000			02287nim a2200541 a 4500
001			HST8228
003			UkLoHST
006			m o h
007			cr nna||||||||
007			sr |mnnnnnzne|
008			210704s2021 enk|||||o||h||||||||eng d
028	5	0	_a8228 _bHenry Stewart Talks
035			_a(UkLoHST)4675
040			_aUkLoHST _beng _cUkLoHST
100	1		_aCrowe, James E. _4spk
245	1	0	_aSARS-COV-2 human monoclonal antibody therapy update _h[electronic resource] / _cJames E. Crowe.
260			_aLondon : _bHenry Stewart Talks, _c2021.
300			_a1 online resource (1 streaming audio file (11 min.)).
490	1		_aInterviews on Covid-19, _x2056-452X
500			_aAudio interview.
500			_aTitle from title frames.
505	0		_aContents: Review of the research done since the start of the pandemic -- Current work covering the SARS-CoV-2 variants -- The selection process of monoclonal antibodies for development -- Next steps in the research and future strategies -- The AHEAD100 project i.e. generating neutralizing antibodies for the 100 most likely causes of future epidemics.
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		0	_aAntiviral agents _xDevelopment.
650		0	_aCoronavirus infections _xChemotherapy.
650		0	_aCoronavirus infections _xImmunological aspects.
650		0	_aCOVID-19 (Disease) _xResearch.
650		0	_aCOVID-19 (Disease) _xTreatment.
650		0	_aDrug development.
650		0	_aMonoclonal antibodies _xResearch.
650		0	_aMonoclonal antibodies _xTherapeutic use.
650		2	_aAntibodies, Monoclonal _xpharmacology.
650		2	_aAntibodies, Monoclonal _xtherapeutic use.
650		2	_aAntibodies, Neutralizing.
650		2	_aAntiviral Agents.
650		2	_aBetacoronavirus _xdrug effects.
650		2	_aCOVID-19 _xdrug therapy.
650		2	_aCOVID-19 _ximmunology.
650		2	_aDrug Discovery.
650		2	_aImmunotherapy.
650		2	_aNeutralization Tests.
650		2	_aPandemics.
650		2	_aSARS-CoV-2 _xdrug effects.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection. _pInterviews on Covid-19.
856	4	0	_uhttps://hstalks.com/bs/4675/
856	4	2	_uhttps://hstalks.com/bs/p/1060/ _3Series
999			_c75734 _d75734